Skye Proxy Sets Vote on Redx Reverse Merger; Skye Holders Could Fall to 0.78%
SKYE is trading near its 52-week low of $1.45 (0.0% above the low) on light trading volume (0.2× avg).
Summary
Skye's preliminary proxy asks holders to approve the Redx reverse merger, a share issuance of up to roughly 794 million shares, and a charter increase to 1.5 billion authorized shares. Existing Skye holders would own about 5.38% of the combined company, or as little as 0.78% if the Specified Adjustment is unresolved.
Key Events · M&A and Partnerships · SKYE
-
Special Meeting Set on Redx Merger
Stockholders will vote on the Transaction Agreement, the Share Issuance Proposal, the Articles Proposal, an advisory Compensation Proposal and an Adjournment Proposal; the board unanimously recommends all five.
-
Skye Holders Cut to 5.38%
At the assumed 0.0892 exchange ratio, pre-deal Skye holders would own about 5.38% of the combined company, Redx holders about 59.74% and PIPE investors about 34.88%.
-
Valuation Floor Cuts Skye to 0.78%
Should the Specified Adjustment remain unresolved at closing, Skye's valuation drops to a $2.0 million floor, the exchange ratio becomes 0.6496 and Skye holders would own about 0.78%.
-
Maximum Issuance of 794 Million Shares
Approval is sought for up to approximately 794,079,692 shares if the Valuation Floor applies, versus approximately 109,218,976 shares at the assumed ratio.
Analysis · SKYE · Life Sciences
Approval of this proxy is effectively a vote on near-total dilution: under the assumed exchange ratio, existing Skye holders would keep only about 5.38% of the combined Fibrx Therapeutics, and as little as 0.78% if the Specified Adjustment is unresolved at closing. The proxy also seeks authority to issue up to roughly 794 million shares in the worst case and to raise authorized Common Stock from 37.5 million to 1.5 billion shares. Behind the board's case is Skye's weak standalone position: Stifel was told that without the deal Skye would likely have to file for bankruptcy or liquidate, with the stock likely worthless. The Skye CVR on nimacimab proceeds is the only retained upside and may pay nothing.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 36.5% of the 953 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKYE was trading at $1.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.4M. The 52-week trading range was $1.45 to $13.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.